Skip to content

Study · Systematic review · 2021

7 results

Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis.

Tsapas A, Karagiannis T, Kakotrichi P, Avgerinos I, Mantsiou C, Tousinas G, Manolopoulos A, Liakos A, Malandris K, Matthews DR, Bekiari E

Diabetes, obesity & metabolism15 Jun 2021Cited by 140 (Europe PMC)

PMID34047443 (opens in a new tab)DOI10.1111/dom.14451 (opens in a new tab)PepBankPUB-34047443
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, subcutaneous semaglutide was the most efficacious glucose-lowering drug for reducing body weight, followed by oral semaglutide.

    In plain wordsIn adults with type 2 diabetes, semaglutide injections cut body weight more than the other diabetes drugs compared. Oral semaglutide ranked next.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight reduction
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · at least 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Subcutaneous semaglutide was the most efficacious in reducing body weight followed by oral semaglutide, exenatide twice-daily, liraglutide, and the sodium-glucose co-transporter-2 (SGLT-2) inhibitors empagliflozin, canagliflozin, dapagliflozin and ertugliflozin.
    2 context sentences
    Summary · context
    We searched Medline, Embase, the Cochrane Library, and grey literature sources until 29 September 2020 for randomized controlled trials of at least 24 weeks' duration assessing the effects of glucose-lowering drugs on body weight and blood pressure in adults with type 2 diabetes.
    Summary · context
    In total, 424 trials (276 336 patients) assessing 21 antidiabetic medications from nine drug classes were included.
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, liraglutide reduced body weight and ranked fourth, after subcutaneous semaglutide, oral semaglutide and exenatide twice-daily.

    In plain wordsIn adults with type 2 diabetes, liraglutide reduced body weight, but less than semaglutide and twice-daily exenatide.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight reduction
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · at least 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Subcutaneous semaglutide was the most efficacious in reducing body weight followed by oral semaglutide, exenatide twice-daily, liraglutide, and the sodium-glucose co-transporter-2 (SGLT-2) inhibitors empagliflozin, canagliflozin, dapagliflozin and ertugliflozin.
    2 context sentences
    Summary · context
    We searched Medline, Embase, the Cochrane Library, and grey literature sources until 29 September 2020 for randomized controlled trials of at least 24 weeks' duration assessing the effects of glucose-lowering drugs on body weight and blood pressure in adults with type 2 diabetes.
    Summary · context
    In total, 424 trials (276 336 patients) assessing 21 antidiabetic medications from nine drug classes were included.
  3. 03HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, semaglutide was among the agents that gave the greatest reductions in systolic blood pressure.

    In plain wordsIn adults with type 2 diabetes, semaglutide was among the diabetes drugs that lowered systolic blood pressure the most.

    Peptide
    Semaglutide
    Outcome
    DecreaseSystolic blood pressure reduction
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · at least 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Subcutaneous semaglutide was the most efficacious in reducing body weight followed by oral semaglutide, exenatide twice-daily, liraglutide, and the sodium-glucose co-transporter-2 (SGLT-2) inhibitors empagliflozin, canagliflozin, dapagliflozin and ertugliflozin. The same agents also conferred the gr…
    2 context sentences
    Summary · context
    We searched Medline, Embase, the Cochrane Library, and grey literature sources until 29 September 2020 for randomized controlled trials of at least 24 weeks' duration assessing the effects of glucose-lowering drugs on body weight and blood pressure in adults with type 2 diabetes.
    Summary · context
    In total, 424 trials (276 336 patients) assessing 21 antidiabetic medications from nine drug classes were included.
  4. 04HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, liraglutide was among the agents that gave the greatest reductions in systolic blood pressure.

    In plain wordsIn adults with type 2 diabetes, liraglutide was among the diabetes drugs that lowered systolic blood pressure the most.

    Peptide
    Liraglutide
    Outcome
    DecreaseSystolic blood pressure reduction
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · at least 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Subcutaneous semaglutide was the most efficacious in reducing body weight followed by oral semaglutide, exenatide twice-daily, liraglutide, and the sodium-glucose co-transporter-2 (SGLT-2) inhibitors empagliflozin, canagliflozin, dapagliflozin and ertugliflozin. The same agents also conferred the gr…
    2 context sentences
    Summary · context
    We searched Medline, Embase, the Cochrane Library, and grey literature sources until 29 September 2020 for randomized controlled trials of at least 24 weeks' duration assessing the effects of glucose-lowering drugs on body weight and blood pressure in adults with type 2 diabetes.
    Summary · context
    In total, 424 trials (276 336 patients) assessing 21 antidiabetic medications from nine drug classes were included.
  5. 05HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, semaglutide reduced diastolic blood pressure.

    In plain wordsIn adults with type 2 diabetes, semaglutide lowered diastolic blood pressure, the lower number in a reading.

    Peptide
    Semaglutide
    Outcome
    DecreaseDiastolic blood pressure reduction
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · at least 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Diastolic blood pressure was reduced with the SGLT-2 inhibitors pioglitazone, exenatide twice-daily and semaglutide.
    2 context sentences
    Summary · context
    We searched Medline, Embase, the Cochrane Library, and grey literature sources until 29 September 2020 for randomized controlled trials of at least 24 weeks' duration assessing the effects of glucose-lowering drugs on body weight and blood pressure in adults with type 2 diabetes.
    Summary · context
    In total, 424 trials (276 336 patients) assessing 21 antidiabetic medications from nine drug classes were included.
  6. 06HumanSystematic reviewEfficacy outcome

    In trials of adults with type 2 diabetes lasting over 52 weeks, semaglutide reduced body weight.

    In plain wordsIn long trials of adults with type 2 diabetes, semaglutide kept body weight lower for more than a year.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight reduction in trials over 52 weeks
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · over 52 weeksAs given in this study (human).

    Source sentences

    Summary
    In subgroup analyses of trials with over 52 weeks' duration, semaglutide and SGLT-2 inhibitors reduced both body weight and systolic blood pressure.
    2 context sentences
    Summary · context
    We searched Medline, Embase, the Cochrane Library, and grey literature sources until 29 September 2020 for randomized controlled trials of at least 24 weeks' duration assessing the effects of glucose-lowering drugs on body weight and blood pressure in adults with type 2 diabetes.
    Summary · context
    In total, 424 trials (276 336 patients) assessing 21 antidiabetic medications from nine drug classes were included.
  7. 07HumanSystematic reviewEfficacy outcome

    In trials of adults with type 2 diabetes lasting over 52 weeks, semaglutide reduced systolic blood pressure.

    In plain wordsIn long trials of adults with type 2 diabetes, semaglutide kept systolic blood pressure lower for more than a year.

    Peptide
    Semaglutide
    Outcome
    DecreaseSystolic blood pressure reduction in trials over 52 weeks
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · over 52 weeksAs given in this study (human).

    Source sentences

    Summary
    In subgroup analyses of trials with over 52 weeks' duration, semaglutide and SGLT-2 inhibitors reduced both body weight and systolic blood pressure.
    2 context sentences
    Summary · context
    We searched Medline, Embase, the Cochrane Library, and grey literature sources until 29 September 2020 for randomized controlled trials of at least 24 weeks' duration assessing the effects of glucose-lowering drugs on body weight and blood pressure in adults with type 2 diabetes.
    Summary · context
    In total, 424 trials (276 336 patients) assessing 21 antidiabetic medications from nine drug classes were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.